pharmaphorum
DECEMBER 2, 2020
Few companies embody the term ‘pharma giant’ as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent German immigrants to the USA, Charles Pfizer and Charles Erhart. Both in their mid-twenties, the two men set up what was initially a fine chemicals business in a Brooklyn factory, using a loan from Pfizer’s father as capital.
Pharma Times
NOVEMBER 30, 2020
Commonly used anti-inflammatory drug added to list of potential treatments
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
NOVEMBER 30, 2020
Researchers at DeepMind say they have solved “the protein folding problem,” a task that has bedeviled scientists for more than 50 years.
Outsourcing Pharma
DECEMBER 1, 2020
Health tech specialists GoodCell are working with the New York Blood Center to identify COVID-19 patients with elevated risk of adverse clinical outcomes.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
DECEMBER 3, 2020
A heart monitor developed by iRhythm has become the first product to be endorsed by NICE in a pilot project covering digital health technologies. In new guidance, the health technology assessment (HTA) agency has recommended iRhythm’s Zio XT service for detecting abnormal heart rhythms – provided NHS organisations that deploy it collect evidence of its benefits.
Pharma Times
DECEMBER 4, 2020
LYT-100 will be evaluated in patients with persistent symptoms caused by COVID-19
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Eye on FDA
DECEMBER 1, 2020
In my last posting on preparedness for a post-vaccination world I touched on some of the questions facing employers in general – policy questions that should be considered now for the eventualities of later. But digging a little deeper, there are also questions to consider with respect to support for ensuring access to vaccines by communities of color.
pharmaphorum
DECEMBER 4, 2020
Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Subject to approval from regulators the vaccine specialist said it plans the trial known as VLA15-221 as a randomised, observer-blind phase 2 study including around 600 healthy people aged 5-65 years of age.
Pharma Times
DECEMBER 2, 2020
First doses for emergency use will be delivered 'immediately'
NY Times
NOVEMBER 30, 2020
The first shots could be given as early as Dec. 21, if authorization is granted.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
NOVEMBER 30, 2020
A recent survey conducted by Oracle reveals trial professionalsâ thoughts, feelings and behavior around decentralized research in the face of the pandemic.
pharmaphorum
DECEMBER 1, 2020
Healthcare agency, consultancy and digital health group Healthware Group has acquired Finland-based digital service development and creative agency Make Helsinki. The acquisition builds on prior collaborations between the two organisations, including in best-in-class full-service agency offerings, digital transformation, technology/enterprise solutions and corporate venturing.
Pharma Times
DECEMBER 2, 2020
Agreement will aim to develop a platform to support radiologists' decision-making
NY Times
DECEMBER 1, 2020
A C.D.C. advisory panel will decide on its recommendations on Tuesday afternoon. Here’s what we expect, along with answers to other questions about the new shot.
Outsourcing Pharma
DECEMBER 1, 2020
Taking place December 9, the Digital Advances in Clinical Trials webinar covers notable advances in clinical trial technology, and the future of the field.
pharmaphorum
DECEMBER 4, 2020
Pfizer slashed its production targets for its COVID-19 vaccine because of a lack of raw materials for its supply chain, according to press reports. The big pharma has said in recent weeks that it expects to produce 50 million doses of the vaccine it developed with the German BioNTech, down from an earlier target of 100 million doses. That’s enough to inoculate 25 million people as the dosing schedule involves two shots three weeks apart.
Pharma Times
DECEMBER 1, 2020
Research conducted at Oxford University used new scanning method
NY Times
NOVEMBER 30, 2020
Multiple inoculations for the coronavirus are making their way through the approval process. Here’s what we know about the plan for their distribution.
Drug Patent Watch
DECEMBER 4, 2020
Annual Drug Patent Expirations for PREVEN+EMERGENCY+CONTRACEPTIVE+KIT Preven Emergency Contraceptive Kit is a drug marketed by Teva Branded Pharm and is included in one NDA. There is one patent protecting this…. The post New patent expiration for Teva Branded drug PREVEN EMERGENCY CONTRACEPTIVE KIT appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
NOVEMBER 30, 2020
Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies. Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment. As AAV is a virus derived from the common cold, the immune system can easily have levels of pre-existing NAbs that will recognise and neutralise AAV, rendering it ineffective.
Pharma Times
NOVEMBER 30, 2020
First biologic to be approved for children aged six to 11 years with condition
NY Times
NOVEMBER 30, 2020
For the 80,000 children who die of H.I.V. each year, drugs are often bitter or hard to swallow. Dolutegravir will soon come in a tasty dissolving tablet.
Pharma Mirror
DECEMBER 4, 2020
Taking a health supplement can positively impact your health and beauty if you choose the right one for your needs. According to Mayo Clinic, the benefits of supplements specifically apply to pregnant people (subject to doctor’s recommendation), over the age of 50, who have food allergies or digestive conditions or miss large food groups in their diet.
pharmaphorum
DECEMBER 4, 2020
Delayed diagnosis, misdiagnosis, and no cure or disease modifying treatments – children living with mitochondrial disease face all the issues often associated with rare diseases. It’s a problem that Michelle Bamber, whose two little girls both have the life-limiting condition, knows only too well. Lily was a happy, contented baby, and her parents had no cause for concern until she went for her two-year check and was put on a pathway to diagnosis.
Pharma Times
DECEMBER 3, 2020
Drug Safety Research Unit set to conduct active surveillance study on COVID-19 vaccines
NY Times
DECEMBER 2, 2020
The company said the trial would involve children ages 12 through 17.
Pharma Mirror
DECEMBER 3, 2020
The keto diet, also known as a ketogenic diet, is a type of food-based lifestyle that many people adopt. Essential, it lets you eat foods that are very high in fat and low in carbohydrates. The keto diet lowers insulin levels and increases your body’s ability to burn fat. This diet type is very alluring as it keeps you healthy and feeling full, unlike other diets.
pharmaphorum
DECEMBER 1, 2020
For so long the US healthcare system was built around the provider, with appointments and services set by the provider (along with insurance reimbursement systems). This structure relies on in-person visits of patients to operate and become profitable. But when the industry suddenly shifted due to COVID-19, so too did the power dynamics of the patient-provider relationship.
Pharma Times
DECEMBER 3, 2020
Partnership will seek to develop small molecules for oncology/immunology targets
NY Times
DECEMBER 2, 2020
China, which has been expanding its presence in the region, is likely to beat the United States in its own backyard with vaccine diplomacy as Washington looks “at taking care of the U.S. first.”.
Drug Patent Watch
DECEMBER 3, 2020
Annual Drug Patent Expirations for VIMPAT Vimpat is a drug marketed by Ucb Inc and is included in three NDAs. It is available from three suppliers. There is one patent…. The post New patent for Ucb Inc drug VIMPAT appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
DECEMBER 3, 2020
Germany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel DNA damage response targets in cancer. The principle of DNA damage response is already being exploited by AstraZeneca and other companies with their poly (ADP-ribose) polymerase (PARP) inhibitor drugs. These target the inherent genetic instability in certain cancer cells, which have switched to a backup mechanism to repair damage to their DNA code.
Pharma Times
NOVEMBER 30, 2020
Survey included input from scientists at The Institute of Cancer Research, London
NY Times
NOVEMBER 30, 2020
Parents should not be afraid of managing the child’s pain with opioids when they are needed, but should make sure a child does not have access to leftover doses.
Drug Patent Watch
DECEMBER 3, 2020
Annual Drug Patent Expirations for JUBLIA Jublia is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There are twelve patents protecting…. The post New patent for Bausch drug JUBLIA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
127 
Let's personalize your content